COBALT

COmBining memantine And cholinesterase inhibitors in Lewy body dementia treatment Trial (COBALT)

The COBALT study is an international research trial designed to explore whether Memantine can be an effective treatment for people with Dementia with Lewy Bodies or Parkinson’s Disease Dementia, who are already taking an Acetylcholinesterase Inhibitors (such as donepezil, rivastigmine, or galantamine).

Dementia with Lewy Bodies and Parkinson’s Disease Dementia are closely related conditions that can cause a variety of challenging symptoms for both individuals and their families. These symptoms can affect memory, thinking, and daily functioning, often leading to increased distress.

One treatment option sometimes prescribed for people with Dementia with Lewy Bodies or Parkinson’s Disease Dementia, is Acetylcholinesterase Inhibitors. These can help improve daily functioning and thinking abilities. Another medication, Memantine, may also help improve cognition, awareness, and the ability to perform everyday tasks. However, it’s still unclear whether using these medications together can offer any additional benefits for those with Dementia with Lewy Bodies or Parkinson’s Disease Dementia.

The trial is being conducted in two parts: COBALT-DLB for those with Dementia with Lewy Bodies, and COBALT-PDD for those with Parkinson’s Disease Dementia.